Wednesday, November 11 - 14:45 GMT
As health economies face challenges of improving outcomes while lowering cost, among many others, a cross-sector approach to health and care is vital. Alongside new biotechnologies and combination therapeutic approaches has come the rapid expansion of AI in multiple settings, new digital technologies and, importantly, the more tech-savvy and engaged patient, convergence is starting to make meaningful impacts. How is the industry developing new core digital capabilities, alliances, partnerships and innovative ways to drive better outcomes?
Melanie Senior, Writer and Analyst (moderator)
Prabhu Velusami, Senior Director, New Ventures and Transactions, Johnson & Johnson
Dan Vahdat, CEO, Huma
Nikolaj Sorensen, CEO, Orexo
Jackie Hunter, Board Director, BenevolentAI
Eric Marcotulli, CEO, Elysium Health
Jackie Hunter is a Board Director of BenevolentAI. Jackie has over thirty years of experience in the bioscience research sector, working across academia and industry including leading neurology and gastrointestinal drug discovery and early clinical development for GlaxoSmithKline. She founded OI Pharma Partners in 2010 to support the life science sector in harnessing the power of open innovation and most recently was Chief Executive of the Biotechnology and Biological Sciences Research Council. She holds a personal chair from St George's Hospital Medical School, which was awarded in recognition of her contribution to bioscience research. In 2010 she was awarded a CBE in the Queen's Birthday Honours list for Services to the Pharmaceutical Industry.